Pancreatic cancer is a highly lethal disease with one of the highest morbidity/mortality ratio among all major
solid cancers. This is partially a result of the frequent failure of diagnostics at its early stages. Scientists and health care
employees worldwide try to find new strategies for early diagnostics of pancreatic cancer. Improved imaging capabilities
have not brought all expected advances yet and could hardly be applied as a first choice screening method in large populations.
Therefore, biomarker research seems to be an attractive option for the screening and diagnostics of pancreatic cancer.
Due to the recent technical innovations, proteomics seems to be a very promising method for biomarkers research at
the time. Recently published studies in this field reveal an increasing number of potential new pancreatic cancer biomarkers,
such as galectins, DJ-1, S100 family proteins, apolipoproteins, transglutaminase 2 and others. Establishment of a sensitive
and specific set of biomarkers will lead to a breakthrough in the pancreatic cancer management and survival. The
most promising proteins with potential to be used in future for early diagnostics and treatment personalization of pancreatic
cancer are reviewed in this manuscript.
Keywords: Apolipoproteins, cancer biomarkers, DJ-1, S100 family proteins, galectins, pancreatic cancer, proteomics,
Rights & PermissionsPrintExport